Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/hematologic-cancers-treatment-regimens/leukemia-treatment-regimens-acute-lymphoblastic-leukemia-all/
NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.
Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians...
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40mins
Axicabtagene ciloleucel is an engineered autologous anti-CD19 chimeric
antigen receptor T cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The product is manufactured in a central
facility from cellular starting material containing...
Συμμετέχοντες: Σαγιαδινού Ε (QM Manager)
Διαρκεια εκπαιδευσης: 8 ώρες
Tύπος εκπαιδευσης: Eξ'αποστασεως
Απονεμήθηκε πιστοποιητικο QMS Internal auditor
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40 mins
In this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with
acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation...
Administration and handling of cell product
Management of Adverse Events
Patient card
Find attached the article ''To Transplant or Not To Transplant in First Remission Acute Lymphoblastic Leukemia? Study group data give some answers, but not all.'' authored by Prof. Spyridonidis and published at American Society for Transplantation and Cellular Therapy
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 40 mins
Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (alloHCT) is recommended in first complete remission (CR1). However, in the...
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 35 mins
With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for...
Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving
more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell
Transplantation from Related Donors: a Study on behalf of the ALWP of the
EBMT
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou
Duration: 40 mins
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou, E. Sagiadinou
Duration: 40 mins
Indications for haematopoietic cell transplantation for
haematological diseases, solid tumours and immune disorders:
current practice in Europe, 2022
Find attached the slides of PeerVoice seminar, presented by Prof Mohty
Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas, Dr Valera.
Duration: 40 mins
Presenter: Prof. Spyridonidis
Participants:Dr Liga, Dr Valera, Dr Tsokanas
Duration: 40 mins
These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to...
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Valera, Dr Tsokanas
Find attached the presentation of Prof. Spyridonidis at 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) that was held on Berlin, 27-30 October 2022
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Valera, Dr. Tsokanas
Duration: 20mins
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hemato-
logic malignancies. Two CAR T products were recently approved in the United States...
https://doi.org/10.1182/blood.2021013290
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 45 min
Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 study evaluating the feasibility of 4...
Presenter: Dr Liga
Participants: Prof. Spyridonidis, Dr Tsokanas, A. Christopoulou, Dr Valera
Duration: 40 mins
Επισυνάπτεται η παρουσίαση του Καθ. Αλέξανδρου Σπυριδωνίδη στην επιστημονική διημερίδα του ΕΟΜ με τίτλο «Βελτιώνοντας τις διαδικασίες και την ποιότητα των μεταμοσχεύσεων στην Ελλάδα», η οποία πραγματοποιήθηκε στις 14 & 15 Οκτωβρίου 2022 στο Μουσείο Μπενάκη
Παρουσίαση: Kαθ. Αλέξανδρος Σπυριδωνίδης
Συμμετέχοντες: Δρ Λίγκα...
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 40 mins
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00223-X/fulltext?dgcid=hubspot_update_feature_updates22_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsmi=229262662&_hsenc=p2ANqtz-_4qThtytktyouVD9PQP8m6s2Fw61Pl4L4GAD65juL7jMS0i30Ms-ENPUL-k5yafQMCP8p8BUvXYXbK66-tdjlqjUP42w&utm_content=229205353&utm_source=hs_email
The effect of the gut microbiota on patients’ outcomes after allogeneic haematopoietic cell transplantation (HCT) is now well established. In particular, gut microbiota dysbiosis has been associated with acute graft-versus-host...